InKine Pharmaceutical Co. Inc. said its pre-colonoscopy bowel-cleansing drug, INKP-102, met or exceeded endpoints in a Phase III trial compared to the company's marketed purgative product, Visicol. (BioWorld Today)

With Positive INKP-102 Results, InKine Prepares For NDA Filing

Feb. 23, 2005

By Jennifer Boggs

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...